Real world experience with Emicizumab in severe haemophilia A (HA) in Senegal, West Africa

被引：0
|
作者：
Diop, Saliou [1 ]
Seck, Moussa [1 ]
Mbomboa, Safiya [1 ]
Martin, Jayson [2 ]
Toure, Sokhna Aissatou [1 ]
Senghor, Alioune Badara [3 ]
Bousso, Elimane Seydi [1 ]
Keita, Mohamed [1 ]
Diallo, Alioune Badara [1 ]
Faye, Blaise Felix [1 ]
Sy, Diariatou [1 ]
Haffar, Assad [2 ]
机构：
[1] Univ Cheikh Anta Diop, Dept Hematol, IHTC Dakar, Dakar, Senegal
[2] World Federat Hemophilia, Montreal, PQ, Canada
[3] Univ Cheikh Anta Diop, Dakar, Senegal
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
Emicizumab; low and middle income countries; prophylaxis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FP-08.04 (
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [1] Real-world data of prophylaxis with emicizumab in children and adolescents with severe haemophilia: A single centre experience
    Michalopoulou, A.
    Dettoraki, A.
    Karelioti, H.
    Thymianou, S.
    Papageorgiou, N.
    Stamati, I.
    Saslis, S.
    Kapsimali, Z.
    Pergantou, H.
    [J]. HAEMOPHILIA, 2024, 30 : 61 - 61
  • [2] Use of emicizumab in patients with haemophilia A: Experience from a treatment centre in, Ghana, West Africa
    Dwuma-Badu, Diana
    Segbefia, Catherine
    Amegan-Aho, Kokou Hefoume
    Peprah, Albert
    Degbotse, Aimee
    Bainson, Samuel
    [J]. HAEMOPHILIA, 2024, 30 : 151 - 151
  • [3] Implementing haemophilia care in Senegal, West Africa
    Diop, S.
    Seck, M.
    Sy-Bah, D.
    Faye, B. F.
    Sow-Ndoye, A.
    Gueye, Y. B.
    Senghor, A. B.
    Sall-Fall, A.
    Toure-Fall, A. O.
    Dieye, T. N.
    Thiam, D.
    Diakhate, L.
    [J]. HAEMOPHILIA, 2014, 20 (01) : 73 - 77
  • [4] Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors
    Hassan, Eman
    Jonathan, Lancashire
    Jayashree, Motwani
    [J]. HAEMOPHILIA, 2021, 27 (06) : E698 - E703
  • [5] Real-world experience with the use of emicizumab in paediatric haemophilia A patients with and without inhibitors
    Lam, Joyce Ching Mei
    Lim, Chiew Ying
    Kadir, Nur Insyirah Abdul
    [J]. HAEMOPHILIA, 2022, 28 : 50 - 51
  • [6] Addressing haemophilia patient education in Senegal, West Africa
    Toure, Sokhna Aissatou
    Seck, Moussa
    Sy, Diariatou
    Loum, Abdoulaye
    Faye, Blaise
    Diallo, Alioune Badara
    Bousso, Elimane Seydi
    Keita, Mohamed
    Mbomboa, Safiya
    Gueye, Serigne
    Senghor, Alioune Badara
    Diop, Saliou
    [J]. HAEMOPHILIA, 2022, 28 : 9 - 9
  • [7] Real-world experience of emicizumab prophylaxis in children with severe haemophilia A: I year follow-up study in egypt
    Sherief, L.
    Hassan, A. S.
    Hamdy, M.
    Darwish, A.
    Nazim, A.
    Hussein, M. A.
    Elgendy, M. R.
    El-assy, O. A.
    [J]. HAEMOPHILIA, 2024, 30 : 121 - 121
  • [8] Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience
    Klamroth, Robert
    Gottstein, Saskia
    [J]. HAEMOPHILIA, 2024,
  • [9] INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA
    Rener, K.
    Pompe, B.
    Doma, S. Anzej
    Kotnik, B. Faganel
    Kitanovski, L.
    Zupan, I. Preloznik
    [J]. HAEMOPHILIA, 2022, 28 : 66 - 66
  • [10] EMICIZUMAB PROPHYLAXIS IN ADULT AND PAEDIATRIC HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS: A SINGLE CENTRE REAL WORLD EXPERIENCE
    Catalano, A.
    Di Gregorio, P.
    Di Cocco, M. L.
    Malizia, R.
    Paolini, F.
    Verna, S.
    [J]. HAEMOPHILIA, 2021, 27 : 70 - 70
12345